CL2023002495A1 - Anticuerpos anti-cd38 para su uso en el tratamiento del rechazo de trasplante mediado por anticuerpos - Google Patents

Anticuerpos anti-cd38 para su uso en el tratamiento del rechazo de trasplante mediado por anticuerpos

Info

Publication number
CL2023002495A1
CL2023002495A1 CL2023002495A CL2023002495A CL2023002495A1 CL 2023002495 A1 CL2023002495 A1 CL 2023002495A1 CL 2023002495 A CL2023002495 A CL 2023002495A CL 2023002495 A CL2023002495 A CL 2023002495A CL 2023002495 A1 CL2023002495 A1 CL 2023002495A1
Authority
CL
Chile
Prior art keywords
antibody
treatment
antibodies
transplant rejection
mediated transplant
Prior art date
Application number
CL2023002495A
Other languages
English (en)
Inventor
Steidl Stefan
Härtle Stefan
Boxhammer Rainer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of CL2023002495A1 publication Critical patent/CL2023002495A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con el uso del anticuerpo anti-CD38 felzartamab en la profilaxis y/o tratamiento del rechazo mediado por anticuerpos (ABMR) de trasplantes. De acuerdo con la presente invención, el felzartamab es efectivo en el tratamiento del rechazo de aloinjerto renal mediado por anticuerpos.
CL2023002495A 2021-03-01 2023-08-23 Anticuerpos anti-cd38 para su uso en el tratamiento del rechazo de trasplante mediado por anticuerpos CL2023002495A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21159860 2021-03-01

Publications (1)

Publication Number Publication Date
CL2023002495A1 true CL2023002495A1 (es) 2023-12-29

Family

ID=74844778

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002495A CL2023002495A1 (es) 2021-03-01 2023-08-23 Anticuerpos anti-cd38 para su uso en el tratamiento del rechazo de trasplante mediado por anticuerpos

Country Status (12)

Country Link
US (1) US20240132618A1 (es)
EP (1) EP4301779A1 (es)
JP (1) JP2024507986A (es)
KR (1) KR20230154239A (es)
AU (1) AU2022230717A1 (es)
BR (1) BR112023016352A2 (es)
CA (1) CA3209172A1 (es)
CL (1) CL2023002495A1 (es)
IL (1) IL304692A (es)
MX (1) MX2023009868A (es)
TW (1) TW202302642A (es)
WO (1) WO2022184676A1 (es)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
RS54056B1 (en) 2004-02-06 2015-10-30 Morphosys Ag ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES
SI2567976T1 (sl) 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
EP2799451A1 (en) 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
EP3284756B1 (en) 2005-10-12 2021-05-05 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
JP5476122B2 (ja) 2006-09-26 2014-04-23 ゲンマブ エー／エス Ｃｄ３８発現腫瘍の併用処置法
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CA2969717A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
BR112017027990A2 (pt) 2015-06-24 2018-08-28 Janssen Biotech, Inc. modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
US20220135695A1 (en) 2019-03-08 2022-05-05 Cedars-Sinai Medical Center Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants
EP3938394A1 (en) 2019-03-15 2022-01-19 MorphoSys AG Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease

Also Published As

Publication number Publication date
TW202302642A (zh) 2023-01-16
WO2022184676A1 (en) 2022-09-09
IL304692A (en) 2023-09-01
AU2022230717A1 (en) 2023-09-14
BR112023016352A2 (pt) 2023-10-03
KR20230154239A (ko) 2023-11-07
US20240132618A1 (en) 2024-04-25
JP2024507986A (ja) 2024-02-21
CA3209172A1 (en) 2022-09-09
EP4301779A1 (en) 2024-01-10
MX2023009868A (es) 2023-08-29

Similar Documents

Publication Publication Date Title
EA202091809A1 (ru) Агонистические антитела против pd-1 и их применение
CL2020002677A1 (es) Receptores quiméricos y metodos de uso de los mismos(divisional de solicitud 2310-2019)
CO2020013392A2 (es) Receptores quiméricos de dll3 y métodos para su uso
CL2021002994A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. (divisional de la solicitud no. 201900067)
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
UY36692A (es) Anticuerpos anti-cd40 y usos de los mismos
PE20190261A1 (es) Anticuerpos que reconocen tau
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
AR108317A1 (es) Composiciones que comprenden coformulación de anticuerpos anti-pd-l1 y anti-ctla-4
AR079458A2 (es) Anticuerpo monoclonal quimerico que se une a cd45
PE20190212A1 (es) Anticuerpos anti_ige
UA112417C2 (uk) Мовчазний fc-варіант анти-cd40 антитіла
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
AR059605A1 (es) Metodos para el uso de anticuerpos contra il-22 humana
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
ECSP22015044A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
AR066411A1 (es) Composicion para el tratamiento de una patologia maligna, de una enfermedad autoinmunitaria o de una enfermedad infecciosa
EA202090922A1 (ru) Композиции и способы истощения cd2+ клеток
EA202092302A1 (ru) Антитела к trem-1 и их применения
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
CL2020002622A1 (es) Anticuerpos anti-cd40 para uso en la prevención del rechazo de injertos
CL2022002501A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y métodos de uso.